Humacyte, Inc. (HUMA) Free cash flow
- Free cash flow · 12 months (USD): Value $-97.56M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -4599.72%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-97.56M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-97.19M − $367.00K ≈ $-97.56M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -4599.72% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-97.56M ÷ $2.12M × 100 ≈ -4599.72% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-97.19M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.00× | Operating cash flow / net income. Period ending 2026-06-30. $-97.19M ÷ $-96.74M ≈ 1.00× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -97.19M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 367.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -97.56M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 2.12M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -96.74M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-97.56M | (m) | $-97.19M | $367.00K | (m) | $2.12M | (m) | $-96.74M | (m) | (m) | -4599.72% | 1.00× |
| 2026-03-31 | $-102.38M | (m) | $-101.55M | $831.00K | (m) | $2.02M | (m) | $-97.59M | (m) | (m) | -5078.17% | 1.04× |
| 2025-12-31 | $-105.93M | (m) | $-105.04M | $884.00K | (m) | $2.04M | (m) | $-40.83M | (m) | (m) | -5197.55% | 2.57× |
| 2025-09-30 | $-106.40M | (m) | $-105.50M | $908.00K | (m) | (m) | (m) | $-36.97M | (m) | (m) | (m) | 2.85× |
| 2025-06-30 | $-106.29M | (m) | $-104.50M | $1.79M | (m) | (m) | (m) | $-58.66M | (m) | (m) | (m) | 1.78× |
| 2025-03-31 | $-100.78M | (m) | $-99.38M | $1.41M | (m) | (m) | (m) | $-77.67M | (m) | (m) | (m) | 1.28× |
| 2024-12-31 | $-99.69M | (m) | $-98.12M | $1.57M | (m) | (m) | (m) | $-148.70M | (m) | (m) | (m) | 0.66× |
| 2024-09-30 | $-92.26M | (m) | $-90.60M | $1.66M | (m) | (m) | (m) | $-152.87M | (m) | (m) | (m) | 0.59× |
| 2024-06-30 | $-81.92M | (m) | $-80.70M | $1.22M | (m) | (m) | (m) | $-139.66M | (m) | (m) | (m) | 0.58× |
| 2024-03-31 | $-83.53M | (m) | $-82.01M | $1.52M | (m) | (m) | (m) | $-105.70M | (m) | (m) | (m) | 0.78× |
| 2023-12-31 | $-75.58M | (m) | $-73.31M | $2.28M | (m) | (m) | (m) | $-110.78M | (m) | (m) | (m) | 0.66× |
| 2023-09-30 | $-76.02M | (m) | $-73.21M | $2.81M | (m) | (m) | (m) | $-89.39M | (m) | (m) | (m) | 0.82× |
| 2023-06-30 | $-79.54M | (m) | $-77.01M | $2.53M | (m) | (m) | (m) | $-88.68M | (m) | (m) | (m) | 0.87× |
| 2023-03-31 | $-73.15M | (m) | $-70.97M | $2.18M | (m) | (m) | (m) | $-29.10M | (m) | (m) | (m) | 2.44× |
| 2022-12-31 | $-72.18M | (m) | $-71.13M | $1.05M | (m) | (m) | (m) | $-11.96M | (m) | (m) | (m) | 5.94× |
| 2022-09-30 | $-74.03M | (m) | $-73.62M | $412.00K | (m) | (m) | (m) | $34.34M | (m) | (m) | (m) | -2.14× |
| 2022-06-30 | $-87.62M | (m) | $-87.33M | $284.00K | (m) | (m) | (m) | $28.06M | (m) | (m) | (m) | -3.11× |
| 2022-03-31 | $-85.66M | (m) | $-85.44M | $213.00K | (m) | (m) | (m) | $-26.01M | (m) | (m) | (m) | 3.29× |
| 2021-12-31 | $-81.41M | (m) | $-81.19M | $220.00K | (m) | (m) | (m) | $-26.48M | (m) | (m) | (m) | 3.07× |
| 2021-09-30 | (m) | (m) | $-59.97M | (m) | (m) | (m) | (m) | $-49.88M | (m) | (m) | (m) | 1.20× |
| 2021-06-30 | (m) | (m) | $-861.89K | (m) | (m) | (m) | (m) | $-7.73M | (m) | (m) | (m) | 0.11× |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |